Globe Newswire HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ( FibroBiologics ), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...\n more…
Ticker Report EF Hutton Acquisition Co. I upgraded shares of FibroBiologics (NASDAQ:FBLG - Free Report) to a strong-buy rating in a research note published on Wednesday morning, Zacks.com reports. FibroBiologics...\n more…
Zolmax EF Hutton Acquisition Co. I upgraded shares of FibroBiologics (NASDAQ:FBLG - Free Report) to a strong-buy rating in a research report released on Wednesday, Zacks.com reports.\nFibroBiologics Stock Up...\n more…
Globe Newswire HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ( FibroBiologics ), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...\n more…
Globe Newswire HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ( FibroBiologics ), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...\n more…